contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


interim-report-first-quarter-2024-january-1-march-31-kancera-ab-publ-orgno-556806-8851

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Kancera is a pharmaceutical company. The company develops pharmaceuticals that counteract injuries in acute and chronic inflammation. The products are developed primarily to counteract hyper-inflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe virus infections. Kancera is planning two Phase II clinical trials, in covid-19 and in cardiac patients. Kancera conducts research and development within Karolinska Institutet Science Park in Stockholm. 

Kancera

The period in brief – financial summary for the first quarter 2024Net sales amounted to SEK 0 million (SEK 0 million)R&D expenses amounted to SEK 11,4 million (SEK 15,2 million)Operating loss...

<div class="mfn-body">The period in brief – financial summary for the first quarter 2024<ul><li>Net sales amounted to SEK 0 million (SEK 0 million)</li><li>R&amp;D expenses amounted to SEK 11,4 million (SEK 15,2 million)</li><li>Operating loss for the quarter amounted to SEK –13,4 million (SEK -17,2 million)</li><li>Loss after financial items for the quarter amounted to SEK –13,0 million (SEK -17,5 million)</li><li>Basic and diluted earnings per share for the quarter amounted to SEK –0,13 (SEK -0,22)</li><li>Cash flow from operating activities for the quarter amounted to SEK –14,7 million (SEK -19,0 million)</li><li>Equity as of March 31, 2024 amounted to SEK 93,9 million (SEK 89,4 million) or SEK 0,77 (SEK 1,12) per share</li><li>The equity ratio on 31 March 2024 was 76 percent (85 percent)</li><li>Cash and cash equivalents on March 31, 2024 amounted to SEK 31,0 million (SEK 76,1 million)</li></ul>Significant events during the first quarter 2024<ul><li>Kancera reported that the company had entered into a license agreement with the University of Newcastle, through which the company retains the exclusive rights to the results and patents from the FRACTAL study.</li><li>Kancera reported that the company’s updated protocol for the Kandova study has been approved in Sweden, Norway and Denmark.</li><li>Kancera reported its intention to carry out a rights issue totaling SEK 121,9 million.</li><li>Kancera reported the outcome of the rights issue; Approximately SEK 73,0 million was raised before issue costs, which corresponded to approximately 60% of the total rights issue.</li></ul>Important events after the end of the period<ul><li>Kancera has reported positive overall results from the phase I study with KAND145</li><li>Kancera has reported that Robert Edfors has been appointed as Chief Scientific Officer and Senior Vice President Clinical Development as from September 1, 2024, and further that Maria Sahlberg has been appointed Vice President Regulatory Affairs &amp; Compliance and Johan Schultz has been appointed Vice President Research &amp; Development Operations.</li></ul>About Kancera AB (publ) Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.For further information Please refer the presentation of the 2024 Q1 Interim Report, available on Kancera’s website: <a rel="noopener" href="http://www.kancera.com/en/investor-relations/presentations/">www.kancera.com/en/investor-relations/presentations/</a>or contact: <a rel="noopener" href="mailto:ir@kancera.com">ir@kancera.com</a> or phone: +46 (0)8-5012 60 80</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/33951b78-312b-4de8-9ecf-6782399bf5f6/kancera-interim-report-2024-q1.pdf" class="mfn-primary">Kancera Interim Report 2024 Q1</a></div>

Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Lääkekehityssijoittaminen: Arvonluonti yrityskaupoilla ja lisensointisopimuksilla

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Pysy ajantasalla Inderesin uutiskirjeillä